Clinical trial · Interventional
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma: Clinical Trail
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
| BCC | Skin Basal Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-Fluorouracil | Drug | Fluorouracil | ALIAS |
| SURGERY | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Patients with intralesional 5-fluorouracil.
- interventionNames
- Drug: 5-Fluorouracil
- type
- ACTIVE_COMPARATOR
- label
- Patients with Surgery
- interventionNames
- Other: SURGERY
Primary outcomes (1)
- measure
- Histologic complete response rate
- timeFrame
- 1 - 2 months
- description
- defined by absence of any tumor on the basis of histologic analysis of the excised specimen.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 5 Years to 90 Years (Child, Adult, Older Adult). * Volunteer to participate in study * Superficial lesion * Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period. Exclusion Criteria: * Ulcerative. * Nodular lesion (x ≥ 1.5 cm)
References
Publications (0)
Data not yet available